Aero plans to launch on Base, Optimism, Arbitrum, and Ethereum mainnet within two weeks, aiming to unify spot-market liquidity across these blockchains. This expansion targets the growing onchain spot market for tokenized equities and foreign exchange, which is crucial for price discovery and market foundation. Aero's developer highlighted that spot trading is the largest opportunity in onchain markets, with spot exchanges generating significant fees. The project aims to replicate its successful liquidity model from Optimism and Base to new networks, potentially expanding the spot market and attracting more trades and revenue.
Aero's upcoming launch across four chains offers context for readers interested in blockchain developments. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 19, 2026 15:02 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell today. Notably, BAL (Balancer) rose by 11.14% to Rp16.297 with a typical hold time of 85 days, contrasting with SXP (Solar) which dropped 46.27% to Rp37 and a typical hold time of 94 days. SAND (The Sandbox) also declined by 8.76% to Rp1.066, with a typical hold time of 123 days and Pluang order activity showing 35% sell versus 65% buy.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
